search
Back to results

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome

Primary Purpose

Nephrotic Syndrome

Status
Completed
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
Mizoribine (MZR)
Cyclophosphamide (CTX)
Sponsored by
Asahi Kasei Pharma Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Nephrotic Syndrome

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients who have medical history with clear documentation of diagnosis of nephrotic syndrome
  • Patient who received renal biopsy within 1 year prior to screening and confirmed the pathologic classification: Minimal Change Disease (MCD), IgA nephropathy, Mesangioproliferative Glomerulonephritis (MsPGN), Membranous Nephropathy (MN), Focal Segmental Glomerulosclerosis (FSGS)
  • Patient with the above different pathologic classification who received adequate hormone therapy more than 8 weeks (including FSGS more than 12 weeks)prior to screening and have 24hr-urine protein≥2.0g/day at screening Adequate hormone dose is defined as prednisone (prednisolone) equivalent dose of 0.8 to 1.0 mg/kg/day (inclusive)
  • Male or female patient between 18 and 70 years (inclusive) at informed consent obtained date
  • Patient with body weight between 40kg and 80kg (inclusive) at screening
  • Patients who sign the informed consent form

Exclusion Criteria:

  • Other primary nephrotic syndrome, e.g. membrano-proliferative glomerulonephritis (MPGN)
  • Secondary nephrotic syndrome (e.g. diabetic nephropathy, anaphylactic purpura nephritis, lupus nephritis, type B hepatitis-related nephritis, renal amyloidosis)
  • Patient who had history of allergy to any investigational product (MZR, CTX) or hormone
  • Patient who had received accumulated dosage of CTX >3g within one year prior to screening
  • Patient who had received immunosuppressant or Chinese traditional medicine with immunosuppressive effect within 30 days prior to screening
  • Patient who received other investigational drugs within 30 days prior to screening
  • Patient who have received plasma exchange therapy or immunoadsorption therapy within 30 days prior to screening
  • Patient who require pentostatin or live vaccine (not including flu vaccine)
  • Patient who is undergoing renal replacement therapy
  • Patient who received kidney transplantation
  • Patient with malignancy
  • Patient with severe hypertension (SBP > 160mmHg or DBP > 100mmHg) which has not been effectively controlled
  • Patient with white blood cell count <3×109/L /L(=3.0 GI/L)
  • Patient with SCr > 176.8μmol/L
  • Patient who has a value that is > 3 times of the upper limit of normal range for AST or ALT
  • Patient with hepatitis B, hepatitis C or HIV infection
  • Patient with other serious infections
  • Patient who is unsuitable for participating in this study in the opinion of investigators ( e.g. uncontrolled diabetes, central nervous system lupus , lupus encephalopathy, active psychosis,osteonecrosis of the femoral head, fulminant hepatitis, peptic ulcer, etc.)
  • Female patient who is pregnant, currently breast feeding or willing to become pregnant
  • Patient with any other diseases that would affect the evaluation of efficacy or safety

Sites / Locations

  • Beijing Friendship Hospital, Capital Medical University
  • Beijing Tongren Hospital, Capital Medical University
  • China-Japan Friendship Hospital
  • Chinese PLA General Hospital
  • The Third Affiliated Hospital of the Third Military Medical University (Daping Hospital)
  • Fuzhou General Hospital of Nanjing Military Region
  • The first Affiliated Hospital of Fujian Medical University
  • The First Affiliated Hospital, Sun Yat-sen University
  • Affiliated Hospital of Guilin Medical University
  • The First Affiliated Hospital of Guangxi Medical University
  • The Third Hospital of Hebei Medical University
  • Wuxi People's Hospital
  • The First Affiliated Hospital of Nanchang University
  • The First Hospital of Jilin University
  • The Second Hospital of Jilin University
  • The First Affiliated Hospital of Dalian Medical University
  • The General Hospital of Shenyang Military Region
  • Shandong Provincial Hospital
  • The General Hospital of Jinan Military Region
  • The Affilited Hospital of Qingdao University
  • Renji Hospital Shanghai Jiaotong University School of Medical
  • Xinhua Hospital Shanghai Jiaotong University School of Medical
  • Zhongshan Hospital Fudan University
  • The Second Hospital of Shanxi Medical University
  • The First Affiliated Hospital of Xi'an Jiaotong University
  • West China Hospital of Sichuan University
  • Kuming General Hospital of Chengdu Military Region
  • The First Affiliated Hospital of College of Medicine, Zhejiang University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Mizoribine (MZR)

Cyclophosphamide (CTX)

Arm Description

Oral administration, daily dose of 150mg (50mg/tablet, t.i.d) All study subjects will receive standard steroid therapies during the study.

Intravenous injection with between 0.5 to 1.0 g/m2 body surface area each time (the maximum dose is 1.0 g/day each time). All study subjects will receive standard steroid therapies during the study.

Outcomes

Primary Outcome Measures

Total Remission rate

Secondary Outcome Measures

Complete Remission rate
Partial Remission rate
Changes of Overall Remission rate
Changes of Complete Remission rate
Changes of Partial Remission rate
Treatment failure rate
Changes and percentage change of 24 hours urine protein and serum albumin from the baseline
Changes of and percentage change of SCr, eGFR and BUN from the baseline
Progression to End-Stage Renal Disease or Doubling of SCr through the study

Full Information

First Posted
October 2, 2014
Last Updated
January 15, 2019
Sponsor
Asahi Kasei Pharma Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT02257697
Brief Title
A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome
Official Title
A Multi-center, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of Mizoribine in Comparison With Cyclophosphamide in the Treatment of Refractory Nephrotic Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
November 2014 (undefined)
Primary Completion Date
November 2018 (Actual)
Study Completion Date
November 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Asahi Kasei Pharma Corporation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To demonstrate that the treatment effect in refractory nephrotic syndrome of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nephrotic Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
239 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Mizoribine (MZR)
Arm Type
Experimental
Arm Description
Oral administration, daily dose of 150mg (50mg/tablet, t.i.d) All study subjects will receive standard steroid therapies during the study.
Arm Title
Cyclophosphamide (CTX)
Arm Type
Active Comparator
Arm Description
Intravenous injection with between 0.5 to 1.0 g/m2 body surface area each time (the maximum dose is 1.0 g/day each time). All study subjects will receive standard steroid therapies during the study.
Intervention Type
Drug
Intervention Name(s)
Mizoribine (MZR)
Other Intervention Name(s)
HE-69
Intervention Type
Drug
Intervention Name(s)
Cyclophosphamide (CTX)
Primary Outcome Measure Information:
Title
Total Remission rate
Time Frame
52 weeks
Secondary Outcome Measure Information:
Title
Complete Remission rate
Time Frame
52 weeks
Title
Partial Remission rate
Time Frame
52 weeks
Title
Changes of Overall Remission rate
Time Frame
8 weeks, 20 weeks, 32 weeks, 44 weeks and 52 weeks
Title
Changes of Complete Remission rate
Time Frame
8 weeks, 20 weeks, 32 weeks, 44 weeks and 52 weeks
Title
Changes of Partial Remission rate
Time Frame
8 weeks, 20 weeks, 32 weeks, 44 weeks and 52 weeks
Title
Treatment failure rate
Time Frame
52 weeks
Title
Changes and percentage change of 24 hours urine protein and serum albumin from the baseline
Time Frame
8 weeks, 20 weeks, 32 weeks, 44 weeks and 52 weeks
Title
Changes of and percentage change of SCr, eGFR and BUN from the baseline
Time Frame
8 weeks, 20 weeks, 32 weeks, 44 weeks and 52 weeks
Title
Progression to End-Stage Renal Disease or Doubling of SCr through the study
Time Frame
52 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients who have medical history with clear documentation of diagnosis of nephrotic syndrome Patient who received renal biopsy within 1 year prior to screening and confirmed the pathologic classification: Minimal Change Disease (MCD), IgA nephropathy, Mesangioproliferative Glomerulonephritis (MsPGN), Membranous Nephropathy (MN), Focal Segmental Glomerulosclerosis (FSGS) Patient with the above different pathologic classification who received adequate hormone therapy more than 8 weeks (including FSGS more than 12 weeks)prior to screening and have 24hr-urine protein≥2.0g/day at screening Adequate hormone dose is defined as prednisone (prednisolone) equivalent dose of 0.8 to 1.0 mg/kg/day (inclusive) Male or female patient between 18 and 70 years (inclusive) at informed consent obtained date Patient with body weight between 40kg and 80kg (inclusive) at screening Patients who sign the informed consent form Exclusion Criteria: Other primary nephrotic syndrome, e.g. membrano-proliferative glomerulonephritis (MPGN) Secondary nephrotic syndrome (e.g. diabetic nephropathy, anaphylactic purpura nephritis, lupus nephritis, type B hepatitis-related nephritis, renal amyloidosis) Patient who had history of allergy to any investigational product (MZR, CTX) or hormone Patient who had received accumulated dosage of CTX >3g within one year prior to screening Patient who had received immunosuppressant or Chinese traditional medicine with immunosuppressive effect within 30 days prior to screening Patient who received other investigational drugs within 30 days prior to screening Patient who have received plasma exchange therapy or immunoadsorption therapy within 30 days prior to screening Patient who require pentostatin or live vaccine (not including flu vaccine) Patient who is undergoing renal replacement therapy Patient who received kidney transplantation Patient with malignancy Patient with severe hypertension (SBP > 160mmHg or DBP > 100mmHg) which has not been effectively controlled Patient with white blood cell count <3×109/L /L(=3.0 GI/L) Patient with SCr > 176.8μmol/L Patient who has a value that is > 3 times of the upper limit of normal range for AST or ALT Patient with hepatitis B, hepatitis C or HIV infection Patient with other serious infections Patient who is unsuitable for participating in this study in the opinion of investigators ( e.g. uncontrolled diabetes, central nervous system lupus , lupus encephalopathy, active psychosis,osteonecrosis of the femoral head, fulminant hepatitis, peptic ulcer, etc.) Female patient who is pregnant, currently breast feeding or willing to become pregnant Patient with any other diseases that would affect the evaluation of efficacy or safety
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Asahi Kasei Pharma Corporation
Organizational Affiliation
Asahi Kasei Pharma Corporation
Official's Role
Study Chair
Facility Information:
Facility Name
Beijing Friendship Hospital, Capital Medical University
City
Beijing
State/Province
Beijing
Country
China
Facility Name
Beijing Tongren Hospital, Capital Medical University
City
Beijing
State/Province
Beijing
Country
China
Facility Name
China-Japan Friendship Hospital
City
Beijing
State/Province
Beijing
Country
China
Facility Name
Chinese PLA General Hospital
City
Beijing
State/Province
Beijing
Country
China
Facility Name
The Third Affiliated Hospital of the Third Military Medical University (Daping Hospital)
City
Chongqing
State/Province
Chongqing
Country
China
Facility Name
Fuzhou General Hospital of Nanjing Military Region
City
Fuzhou
State/Province
Fujian
Country
China
Facility Name
The first Affiliated Hospital of Fujian Medical University
City
Fuzhou
State/Province
Fujian
Country
China
Facility Name
The First Affiliated Hospital, Sun Yat-sen University
City
Guangzhou
State/Province
Guangdong
Country
China
Facility Name
Affiliated Hospital of Guilin Medical University
City
Guilin
State/Province
Guangxi
Country
China
Facility Name
The First Affiliated Hospital of Guangxi Medical University
City
Nanning
State/Province
Guangxi
Country
China
Facility Name
The Third Hospital of Hebei Medical University
City
Shijiazhuang
State/Province
Hebei
Country
China
Facility Name
Wuxi People's Hospital
City
Wuxi
State/Province
Jiangsu
Country
China
Facility Name
The First Affiliated Hospital of Nanchang University
City
Nanchang
State/Province
Jiangxi
Country
China
Facility Name
The First Hospital of Jilin University
City
Changchun
State/Province
Jilin
Country
China
Facility Name
The Second Hospital of Jilin University
City
Changchun
State/Province
Jilin
Country
China
Facility Name
The First Affiliated Hospital of Dalian Medical University
City
Dalian
State/Province
Liaoning
Country
China
Facility Name
The General Hospital of Shenyang Military Region
City
Shenyang
State/Province
Liaoning
Country
China
Facility Name
Shandong Provincial Hospital
City
Jinan
State/Province
Shandong
Country
China
Facility Name
The General Hospital of Jinan Military Region
City
Jinan
State/Province
Shandong
Country
China
Facility Name
The Affilited Hospital of Qingdao University
City
Qingdao
State/Province
Shandong
Country
China
Facility Name
Renji Hospital Shanghai Jiaotong University School of Medical
City
Shanghai
State/Province
Shanghai
Country
China
Facility Name
Xinhua Hospital Shanghai Jiaotong University School of Medical
City
Shanghai
State/Province
Shanghai
Country
China
Facility Name
Zhongshan Hospital Fudan University
City
Shanghai
State/Province
Shanghai
Country
China
Facility Name
The Second Hospital of Shanxi Medical University
City
Taiyuan
State/Province
Shanxi
Country
China
Facility Name
The First Affiliated Hospital of Xi'an Jiaotong University
City
Xian
State/Province
Shanxi
Country
China
Facility Name
West China Hospital of Sichuan University
City
Chengdu
State/Province
Sichuan
Country
China
Facility Name
Kuming General Hospital of Chengdu Military Region
City
Kunming
State/Province
Yunnan
Country
China
Facility Name
The First Affiliated Hospital of College of Medicine, Zhejiang University
City
Hangzhou
State/Province
Zhejiang
Country
China

12. IPD Sharing Statement

Learn more about this trial

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome

We'll reach out to this number within 24 hrs